Duration to Hold GLP-1 Receptor Agonists Before Sedation
For patients taking GLP-1 receptor agonists for weight loss, hold the medication for at least three half-lives before any procedure requiring sedation or general anesthesia; for patients with type 2 diabetes, consult endocrinology but strongly consider the same three half-life hold unless glycemic risks outweigh aspiration concerns. 1
Specific Holding Periods by Medication
Based on pharmacokinetic data, the three half-life rule translates to:
Semaglutide (Ozempic/Wegovy): 21 days (3 weeks) before procedure
- Half-life: 7 days 2
Tirzepatide (Mounjaro): 15 days before procedure
- Half-life: 5 days 2
Dulaglutide (Trulicity): 13-14 days before procedure
- Half-life: 4.5-4.7 days 2
This three half-life approach clears approximately 88% of the drug from the system 1.
Critical Distinction: Weight Loss vs. Diabetes Indication
The most recent 2025 multidisciplinary consensus 2 and 2024 guidelines [1-1] emphasize a fundamental difference in approach:
For Weight Loss Patients (Non-Diabetic)
Hold for three half-lives without exception. The risks clearly outweigh benefits since there is no glycemic control imperative. Higher doses used for weight management cause more prolonged gastric stasis, and discontinuation for only 7 days has been shown insufficient to ensure gastric emptying 1.
For Type 2 Diabetes Patients
Endocrinology consultation is mandatory to weigh:
- Risk of aspiration from delayed gastric emptying (OR 10.23 for pulmonary aspiration in elective surgery 2)
- Benefits of continued therapy: improved perioperative glycemic control, lower postoperative insulin requirements, reduced hypoglycemia risk, and improved cardiovascular outcomes 2
- Need for bridging diabetic therapy if holding beyond next scheduled dose [1-1]
Recent evidence shows no significant difference in perioperative glycemic control whether GLP-1 RAs are held or continued 3, which may tip the balance toward holding for safety.
High-Risk Situations Requiring Extended Hold or Postponement
Proceed with extreme caution or postpone if patient has:
- Recently started medication or had dose escalation
- Active nausea, vomiting, or abdominal distention
- Inability to hold medication for three half-lives 1
Common pitfall: The older ASA recommendation of holding daily doses "the day before" or weekly doses "one week before" is insufficient and outdated 4. This does not adequately clear the medication.
Risk Mitigation Strategies When Holding Is Inadequate
If the patient cannot hold for three half-lives or presents emergently:
- Gastric ultrasound to assess residual volume (proceed if <1.5 mL/kg) 1
- Prokinetic agents (metoclopramide or erythromycin) preoperatively 1
- Clear liquid diet for extended period before NPO time 1
- Rapid sequence intubation with full aspiration precautions 1
- Gastric decompression in very high-risk cases 1
Special Consideration: Concurrent Colonoscopy
Recent 2026 data shows that patients undergoing concurrent colonoscopy (requiring clear liquids the day prior) had zero clinically significant retained gastric volume events, even with continued GLP-1 RA use 5. The clear liquid preparation appears protective. However, for EGD-only procedures, continuing medication resulted in 46.7% clinically significant retained gastric contents versus 5.0% when held 5.
When to Resume After Procedure
The evidence focuses entirely on preoperative holding; no specific guidance exists for postoperative resumption. Use clinical judgment based on:
- Return of normal gastric function
- Adequate oral intake tolerance
- Resolution of postoperative nausea/ileus
Standard practice would be to resume once tolerating regular diet, typically within 24-48 hours for minor procedures.
Obesity as Independent Risk Factor
Even with a two-week hold, patients with BMI ≥28 kg/m² showed tenfold higher risk of retained gastric contents compared to no GLP-1 use 6. Obesity itself compounds the aspiration risk, necessitating heightened vigilance regardless of medication cessation duration.